TECHNOLOGY SEED

  • Life science

Why our original Lipid Nano Particles have obtained agreements with 29 companies?

eyecatch image

Our Original Lipids

Nanomedicines extend drug therapy from small molecular compounds to proteins/nucleic acids/genes. A lipid nanoparticle (LNP) is one of the promising nano-carrier but a less efficiency or low endosomal release is a major problem. A pH-responsive cationic lipid is a solution and its clinical effectiveness has been demonstrated in COVID-19 vaccines.
We have established a library of pH-responsive cationic lipids. In this library, our LNP showed high efficiency in endosomal release with ED50 values of 0.002mg/kg. Our LNP has exhibited better properties than other clinically used LNPs.
Due to its promising data and high potentials, our lipids have drawn interest of many companies from Mega pharma to Biotech worldwide for the carrier of mRNA, siRNA and Cas9, and Hokkaido University successful has signed the agreements under its original license scheme.

 

Feature

  1. We have a LNP library in which there can be suitable one for your molecule delivery.
  2. We obtained the LNP with the best efficiency in public in endosomal release.
  3. We have know-how to develop best lipids for target cells and tissues.

 

We are looking for a partner that will use some novel LNPs in our library for a drug delivery.
We can share more data with you under CDA and provide you with our LNPs for your evaluation under MTA. Collaborative research is also available.

sample post

sample post

Data

LNPs in our library demonstrated the efficacies as a carrier by the following experiments:

  • mRNA Delivery in vivo
  • Safety data/Hematological parameters,etc.
  • LNP specific for The Hepatic Stellate Cells
  • A Selective formulation for the Dendritic Cells in the spleens
  • LNP for the Lung delivery
  • Cas9 ribonucleoprotein (RNP) delivery
  • Cancer immunotherapy by STING ligand loaded nano DDS
  • siRNA delivery to human immune cells
  • LNP specific for The Hepatic Stellate Cells
  • A Selective formulation for the Dendritic Cells in the spleens
  • LNP for the Lung delivery
  • Cas9 ribonucleoprotein (RNP) delivery
  • Cancer immunotherapy by STING ligand loaded nano DDS
  • siRNA delivery to human immune cells

Applications:Drug delivery application for siRNA, mRNA, Cas9 and plasmid DNA ,etc.

 

Patents

2019-525575（Japan）
16/622109（US）
201880038874.2（China）
18816591.4（Europe）
10-2019-7036750（Korea）
3067192（Canada）
6570188（Japan）
10182987（US）
15796352.1（Europe）
2022-060960（Japan）
2022-076251（Japan）

BACK
CONTACT
Boston